Market Size of Hepatorenal Syndrome Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hepatorenal Syndrome Treatment Market Analysis
The hepatorenal syndrome treatment market is projected to record a CAGR of nearly 6.2% over the forecast period. Hepatorenal syndrome is a type of progressive kidney failure seen in people with severe liver damage, most often caused by cirrhosis. As the kidneys stop functioning, toxins begin to build up in the body. Eventually, this leads to liver failure. The major factor attributing to the growth of the market is the increase in the prevalence of liver damage and cirrhosis. According to the Centers for Disease Control and Prevention, 4.5 million adults are diagnosed with chronic liver disease in the year 2018, in the United States alone. Furthermore, increasing fast-track and orphan drug designations boosts the market growth. However, side effects with the drugs and stringent regulations are restraining the market growth.
